Stock LEGN LEGEND BIOTECH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
43.52 USD +1.00% Intraday chart for Legend Biotech Corporation +7.51% -27.67%
06-17 Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target MT
06-03 Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses
MT
Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA
CI
Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
CI
MaxCyte inks deal with Legend Biotech for tech supply
AN
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program
MT
Legend Expects to Log Profit in 2026
MT
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday
MT
Sector Update: Health Care
MT
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell
MT
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales
DJ
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q1 Revenue $94M
MT
Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer
MT
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
CI
US FDA mandates label updates on CAR-T cancer therapies
RE
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug
MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
MT
U.S. FDA approves expanded use of J&J's cancer cell therapy
RE
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. News Legend Biotech Corporation
  5. Highlights